BASF is now proposing a cash offer of €684 million (approximately USD 912 million), up from its original bid of €644 million.
BASF (Ludwigshafen, Germany) upped its proposal bid to acquire Pronova BioPharma (Lysaker, Norway), owner of the patent for omega-3 cardiovascular health drug Lovaza. BASF is now proposing a cash offer of €684 million (approximately USD 912 million), up from its original bid of €644 million.
Earlier this month, BASF extended its deadline for the acquisition offer to January 18. It says this deadline for a decision from remaining shareholders will not be extended. The company says it has so far received acceptances from those owning 70% of Pronova’s shares; it needs acceptance from more than 90%.
“We thank all those shareholders of Pronova who have accepted the offer to date. Following a comprehensive due diligence review, and taking into account the opportunities and foreseeable risks in Pronova’s business, this increased offer is our last, best, and final offer,” stated Michael Heinz, a member of BASF’s board of executive directors, in a press release.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.